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A proportion of pandemic flu cases requires critical care.
Several risk factors are associated with progressive illness.
The World Health Organization recommends prompt antiviral
treatment when risk factors are present [1]. Nevertheless, in
Rello and colleagues’ work, 15 out of 32 critical pandemic flu
patients did not have any risk factor [2].
In our hospital, 25 pandemic flu cases have been diagnosed
by RT-PCR thus far. Three of these cases required critical
care. Noteworthy, those patients had been visited in
emergency services 2 to 3 days before. The clinical picture
did not prompt the physician to prescribe any antiviral, and
oseltamivir treatment was delayed 5 days or more. In contrast,
in the group of patients who did not require critical care (22
patients), only three patients had a prior emergency visit
(Fisher’s exact test P = 0.009) and 18 patients received
antiviral treatment in the first 48 hours of symptoms (Fisher’s
exact test P = 0.009).
In Rello and colleagues’ study, the median number of days
from illness onset to initiation of antiviral treatment was 4
days. Patients with risk factors were probably treated
immediately, however, and patients without any risk factors
were probably treated later. Some evidence suggests that
early antiviral treatment is associated with a good prognosis
[3]. Rello and colleagues may provide the mean of treatment
delay days in patients without any risk factor and any
putative differences with the rest of patients. Early antiviral
treatment with active antiviral drugs may prevent severe
cases in patients without any risk factor. The authors may
also inform about any other difference in this group of
patients.
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PCR = polymerase chain reaction; RT = reverse transcriptase.
Authors’ response
Jordi Rello and Alejandro Rodríguez, for the H1N1 SEMICYUC Working Group
We appreciate the interest from Dr Alonso-Tarrés and
colleagues in our article and their insightful observations
regarding management of severe influenza A (H1N1)v. We
agree that several points about antiviral treatment should be
clarified.
Recent observational studies suggested that antiviral
treatment started within 4 days after illness onset may reduce
mortality among adult patients hospitalized with influenza [4]
and may enhance viral load decrease and viral clearance [5].
In our study, no significant delay in the first dose of antiviral
was observed in patients with comorbidities (6.5 ± 5.0,
median 6 days) versus those without comorbidities (4.5 ± 3.8,
median 4 days) [2]. No differences were observed regarding
the severity of illness (Acute Physiology and Chronic Health
Evaluation II score, 12.9 ± 7.9 vs. 14.5 ± 5.9; P = 0.50),
organ dysfunction (Sequential Organ Failure Assessment
score, 6.9 ± 4.2 vs. 6.2 ± 2.0; P = 0.54) or mortality (26.7%
vs. 23.5%; P = 0.98) between groups.
In a recent multicenter observational study [6], however,
receipt of antiviral drugs in <48 hours was the only variable
associated with positive outcome. In our study, eight (25%)
patients received antiviral therapy within 48 hours after onset
of symptoms, and one patient died (12.5%) [2]. Delayed
initiation of antiviral therapy (>48 hours) was associated with
high risk of death (odds ratio = 2.90, 95% confidence interval =
0.30 to 28.0) and a mortality of 29.7%.Critical Care    Vol 13 No 6 Alonso-Tarrés et al.
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Whereas randomized controlled trials are warranted to prove
clinical benefit of early antiviral therapy, current observations
suggest that a delay in antiviral therapy may contribute to
increase the viral load, to delay shedding and to complica-
tions. Prompt diagnosis and early antiviral prescription should
therefore be considered in patients with influenza-like illness
for 2009 pandemic influenza.
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